Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma

Japanese Journal of Cancer Research

Volumn 93, Issue 4, 2002, Pages 363-368

  Peng, Bao Gang ^a,c   Liu, Shu Qin ^b   Kuang, Ming ^c   He, Qiang ^c   Totsuka, Saeri ^a   Huang, Lan ^a   Huang, Jiefu ^c   Lu, Ming De ^c   Liang, Li Jing ^c   Leong, Kam W ^b   Ohno, Tadao ^a  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b Johns Hopkins University   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clinical trial; Hepatocellular carcinoma; Immunotherapy; Tumor vaccine

Indexed keywords

ADJUVANT; AUTOANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUBERCULIN; TUMOR VACCINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG RESPONSE; ENCAPSULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROVOCATION TEST; TUMOR BIOPSY;

ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLINICAL TRIALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECURRENCE; TIME FACTORS;

EID: 18344392456     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01265.x     Document Type: Article

References (30)

1. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide
2. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells
3. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
4. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells
5. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
6. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine
7. Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells
8. The challenge of fetal gene therapy
9. Liposomal gene delivery: A complex package
10. Immunotherapy: Natural versus synthetic peptides
11. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptidies elicit protective and therapeutic antitumour immunity
12. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
13. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
14. Cancer vaccines
15. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections
16. Tumor-specific autologous cytotoxic T lymphocytes from tissue sections
17. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells
18. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
19. Natural adjuvants: Endogenous activators of dendritic cells
20. Expression of liver phenotypes in cultured mouse hepatoma cells
21. Importance of antigen-lymphocyte interaction in establishment of cellular immunity
22. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients
23. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial
24. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
25. Phagocytic processing of exogenous particulate antigen by macrophages for presentation by class I MHC molecules
26. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
27. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway
28. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocytes responses in vitro
29. + T cells in vitro
30. Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages